Løvschall, C., Risør, B. W., Tayyari Dehbarez, N., Jensen, L. G., Lou, S., Carstensen, K., Steen Boisen, A. S., Ladehoff Thomsen, A. M., Thirup, L., Jensen, A. H., Just Nielsen, S.
, Rodkjær, L. Ø., Storgaard, M., Hjorth, U., Fridthjof, K. S., Truelshøj, T., Lyng, H., Rosenbrandt , H. B. & Therkelsen, S. C. (2021).
Outpatient Parenteral Antibiotic Therapy – A Health Technology Assessment. Defactum.
Østergaard, L., Vesikari, T., Senders, S. D., Flodmark, C. E., Kosina, P., Jiang, H. Q., Maguire, J. D., Absalon, J., Jansen, K. U., Harris, S. L., Maansson, R., Balmer, P., Beeslaar, J. & Perez, J. L. (2021).
Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months.
Vaccine,
39(32), 4545-4554.
https://doi.org/10.1016/j.vaccine.2021.06.005